Search Results

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

HUTCHMED Limited announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024.

Axena Health, Inc., a medical device company focused on female pelvic health, has closed on an additional $9.4 million in its Series A fundraising.

Alpha-9 Oncology announced that the first participant has been dosed in the Phase 1 study evaluating 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor for the imaging of locally advanced or metastatic melanoma.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced the completion of the full exercise of 12.9 million Series H warrants.

Simulations Plus, Inc. today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.

ERS Genomics Limited, the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, announced a non-exclusive CRISPR/Cas9 license agreement.

AstraZeneca on Wednesday unveiled Phase I results for its PCSK9 inhibitor, acquired from Dogma Therapeutics in 2020, which when combined with a statin reduced LDL-C levels in patients with high “bad” cholesterol.

Cutera, Inc. today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024.

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of action for the degradation of BRD9 – completely differentiated from cereblon- or VHL-based PROTACs.